nach oben

Journal of Business Ethics

Erschienen in:

31.07.2018 | Original Paper

Stakeholder Orientation and Market Impact: Evidence from India

verfasst von: Arzi Adbi, Ajay Bhaskarabhatla, Chirantan Chatterjee

Erschienen in: Journal of Business Ethics | Ausgabe 2/2020

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

This study integrates insights from stakeholder theory and the literature on competitive dynamics and incumbent responses to entry. While research in economics and strategy has examined how market incumbents respond to new entrants, little is known about the heterogeneity in these responses to the entry of a stakeholder-oriented firm; our study addresses this research gap. Findings from a novel, longitudinal dataset of 206 granularly defined pharmaceutical markets in India suggest that stakeholder-oriented firm entry in these markets is associated with an impact on prices and product differentiation with heterogeneous responses from high-end and low-end incumbents. Specifically, entry by a stakeholder-oriented firm results in a reduction in prices and dosage sizes from high-end incumbents, whereas low-end incumbents respond in the opposite direction.

Vorheriger Artikel CEO Hubris and Firm Pollution: State and Market Contingencies in a Transitional Economy

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Nur mit Berechtigung zugänglich

For a reference to additional robustness in our online supplement here and later, see: online supplement to this article: https://www.dropbox.com/s/2wt6x4elt94zei9/OnlineSupplement-StakeholderOrientationandMarketImpact.pdf?dl=0.

Amaldoss, W., & Shin, W. (2011). Competing for low-end markets. Marketing Science, 30(5), 776–788.

Ashraf, N., & Bandiera, O. (2017). Altruistic capital. American Economic Review, 107(5), 70–75.

Balotsky, E. R. (2009). Where strategy and ethics converge: Pharmaceutical industry pricing policy for Medicare part D beneficiaries. Journal of Business Ethics, 84, 75–88.

Bate, R., Jin, G. Z., & Mathur, A. (2011). Does price reveal poor-quality drugs? Evidence from 17 countries. Journal of Health Economics, 30(6), 1150–1163.

Bennett, D., & Yin, W. (2018). The market for high-quality medicine: Retail chain entry and drug quality in India. Review of Economics and Statistics (forthcoming).

Berman, S. L., Wicks, A. C., Kotha, S., & Jones, T. M. (1999). Does stakeholder orientation matter? The relationship between stakeholder management models and firm financial performance. Academy of Management Journal, 42(5), 488–506.

Berry, S. (1992). Estimation of a model of entry in the airline industry. Econometrica, 60(4), 889–917.

Besley, T., & Ghatak, M. (2017a). Profit with purpose? A theory of social enterprise. American Economic Journal: Economic Policy, 9(3), 19–58.

Besley, T., & Ghatak, M. (2017b). Pro-social motivation and incentives. Annual Review of Economics, 18 (forthcoming).

Bhaskarabhatla, A., & Chatterjee, C. (2017). The role of physicians in prescribing irrational fixed-dose combination medicines in India. Social Science & Medicine, 174, 179–187.

Bhaskarabhatla, A., Chatterjee, C., Anurag, P., & Pennings, E. (2016). Mitigating regulatory impact: The case of partial price controls on metformin in India. Health Policy and Planning, 32(2), 194–204.

Bisserbe, N. (2009). Testing Times for Mankind Pharma: The rising star needs new strategies to sustain its robust growth. BusinessWorld, November Issue.

Borenstein, S. (1989). Hubs and high fares: dominance and market power in the U.S. airline industry. Rand Journal of Economics, 20(3), 344–365.

Bosse, D. A., Phillips, R. A., & Harrison, J. S. (2009). Stakeholders, reciprocity, and firm performance. Strategic Management Journal, 30(4), 447–456.

Bunch, D. S., & Smiley, R. (1992). Who deters entry? Evidence on the use of strategic entry deterrents. Review of Economics and Statistics, 74(3), 509–521.

Business Standard. (2012). Mankind Pharma set to tap core drugs market, July 19.

Capps, C., Carlton, D. W., & David, G. (2017). Antitrust treatment of nonprofits: Should hospitals receive special care? (p. w23131) Cambridge: National Bureau of Economic Research.

Casadesus-Masanell, R., & Ghemawat, P. (2006). Dynamic mixed duopoly: A model motivated by Linux vs. Windows. Management Science, 52(7), 1072–1084.

Casadesus-Masanell, R., & Llanes, G. (2011). Mixed source. Management Science, 57(7), 1212–1230.

Caves, R. E., & Porter, M. E. (1977). From entry barriers to mobility barriers: Conjectural decisions and contrived deterrence to new competition. Quarterly Journal of Economics, 91(2), 241–261.

Chatterjee, C., Kubo, K., & Pingali, V. (2015). The consumer welfare implications of governmental policies and firm strategy in markets for medicines. Journal of Health Economics, 44, 255–273.

Chaudhuri, S., Goldberg, P. K., & Jia, P. (2006). Estimating the effects of global patent protection in pharmaceuticals: A case study of quinolones in India. American Economic Review, 96(5), 1477–1514.

Cockburn, I. M., Lanjouw, J. O., & Schankerman, M. (2016). Patents and the global diffusion of new drugs. American Economic Review, 106(1), 136–164.

Constantatos, C., & Perrakis, S. (1997). Vertical differentiation: Entry and market coverage with multiproduct firms. International Journal of Industrial Organization, 16(1), 81–103.

Cool, K., Röller, L. H., & Leleux, B. (1999). The relative impact of actual and potential rivalry on firm profitability in the pharmaceutical industry. Strategic Management Journal, 20(1), 1–14.

Davis, S., Murphy, K., & Topel, R. (2004). Entry, pricing, and product design in an initially monopolized market. Journal of Political Economy, 112(1), 188–225.

De Fraja, G., & Delbono, F. (1989). Alternative strategies of a public enterprise in oligopoly. Oxford Economic Papers, 41, 302–311.

Deneffe, D., & Masson, R. T. (2002). What do not-for-profit hospitals maximize? International Journal of Industrial Organization, 20, 461–492.

Deshpande, R., & Winig, L. 2006. Cipla. Harvard Business School Case 503 – 085.

Devinney, T. M., Mcgahan, A. M., & Zollo, M. (2013). A research agenda for global stakeholder strategy. Global Strategy Journal, 3(4), 325–337.

Donaldson, T.. Preston, L. E. (1995). The stakeholder theory of the corporation: Concepts, evidence, and implications. Academy of Management Review, 20(1), 65–91.

Dranove, D., & Ludwick, R. (1999). Competition and pricing by nonprofit hospitals: A reassessment of Lynk’s analysis. Journal of Health Economics, 18(1), 87–98.

Duggan, M. (2000). Hospital market structure and the behavior of not-for-profit hospitals. Rand Journal of Economics, 33(3), 433–446.

Dutta, A. (2011). From free entry to patent protection: Welfare implications for the Indian pharmaceutical industry. Review of Economics and Statistics, 93(1), 160–178.

Emanuel, E. (1999). Choice and representation in health care. Medical Care Research and Review, 56(1), 113–140.

Evans, W. N., & Kessides, I. N. (1993). Localized market power in the US airline industry. Review of Economics and Statistics, 75(1), 66–75.

Fiss, P. C., & Zajac, E. J. (2004). The diffusion of ideas over contested terrain: The (non) adoption of a shareholder value orientation among German firms. Administrative Science Quarterly, 49(4), 501–534.

Flammer, C., & Bansal, P. (2017). Does a long-term orientation create value? Evidence from a regression discontinuity. Strategic Management Journal, 38(9), 1827–1847.

Flammer, C., & Kacperczyk, A. (2016). The impact of stakeholder orientation on innovation: Evidence from a natural experiment. Management Science, 62(7), 1982–2001.

Frank, R. G., & Salkever, D. (1992). Pricing, patent loss and the market for pharmaceuticals. Southern Economic Journal, 59(2), 165–179.

Frank, R. G., & Salkever, D. (1997). Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy, 6, 75–90.

Frank, R. G., & Salkever, D. S. (1991). The supply of charity services by nonprofit hospitals: Motives and market structure. Rand Journal of Economics, 22(3), 430–445.

Freeman, R. E. (2008). Ending the so-called ‘Friedman-Freeman’ debate. Business Ethics Quarterly, 18(2), 153–190.

Freeman, R. E. (2010). Managing for stakeholders: Trade-offs or value creation. Journal of Business Ethics, 96, 7–9.

Freeman, R. E., Harrison, J. S., Wicks, A. C., Parmar, B. L., & De Colle, S. (2010). Stakeholder Theory: The State of the Art. Cambridge: Cambridge University Press.

Freeman, R. E., Martin, K., & Parmar, B. (2007). Stakeholder capitalism. Journal of Business Ethics, 74, 303–314.

Freeman, R. E., Wicks, A. C., & Parmar, B. (2004). Stakeholder theory and “the corporate objective revisited”. Organization Science, 15(3), 364–369.

Friedman, M. (1970). The social responsibility of business is to increase its profits. New York Times Magazine, 13, 32–33.

Froot, K. A., Perold, A. F., & Stein, J. C. (1992). Shareholder trading practices and corporate investment horizons. Journal of Applied Corporate Finance, 5(2), 42–58.

Gaynor, M., Ho, K., & Town, R. J. (2015). The industrial organization of health-care markets. Journal of Economic Literature, 53(2), 235–284.

Geroski, P. (1995). What do we know about entry? International Journal of Industrial Organization, 13, 421–440.

Gilmartin, M. J., & Freeman, R. E. (2002). Business ethics and health care: A stakeholder perspective. Health Care Management Review, 27(2), 52–65.

Goolsbee, A., & Syverson, C. (2008). How do incumbents respond to the threat of entry? Evidence from the major airlines. Quarterly Journal of Economics, 123(4), 1611–1633.

Grabowski, D. C., & Hirth, R. A. (2003). Competitive spillovers across non-profit and for-profit nursing homes. Journal of Health Economics, 22(1), 1–22.

Grabowski, H. G., & Vernon, J. M. (1992). Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics, 35(2), 331–350.

Grilo, I. (1994). Mixed duopoly under vertical differentiation. Annals of Economics and Statistics, 33, 91–112.

Hansmann, H. B. (1987). Economic theories of non-profit organizations. In W. W. Powell (Ed.), The non-profit sector: A research handbook (pp. 27–42). Bellevue, WA: Yale University Press.

Hemphill, T. A. (2010). Extraordinary pricing of orphan drugs: Is it a socially responsible strategy for the US pharmaceutical industry? Journal of Business Ethics, 94(2), 225–242.

Henisz, W. J., Dorobantu, S., & Nartey, L. (2014). Spinning gold: The financial returns to external stakeholder engagement. Strategic Management Journal, 35(12), 1727–1748.

Hirth, R. A. (1997). Competition between for-profit and nonprofit health care providers: Can it help achieve social goals? Medical Care Research and Review, 54(4), 414–438.

Hirth, R. A. (1999). Consumer information and competition between nonprofit and for-profit nursing homes. Journal of Health Economics, 18(2), 219–240.

Ishibashi, I., & Matsushima, N. (2009). The existence of low-end firms may help high-end firms. Marketing Science, 28(1), 136–147.

Ishibashi, I., & Matsumura, T. (2006). R&D competition between public and private sectors. European Economic Review, 50(6), 1347–1366.

Jain, T., Aguilera, R. V., & Jamali, D. (2017). Corporate stakeholder orientation in an emerging country context: A longitudinal cross industry analysis. Journal of Business Ethics, 143(4), 701–719.

Jones, T. M. (1995). Instrumental stakeholder theory: A synthesis of ethics and economics. Academy of Management Review, 20(2), 404–437.

Kakkar, H. (2011). A giant leap for mankind: From small beginnings, mankind is set to take the pharma sector by storm. Outlook Business Magazine, December 24.

Kapczynski, A. (2009). Harmonization and its discontents: A case study of TRIPS implementation in India’s pharmaceutical sector. California Law Review, 97, 1571–1650.

Khanna, N., & Tice, S. 2000. Strategic responses of incumbents to new entry: The effect of ownership structure, capital structure, and focus. Review of Financial Studies, 13(3), 749–779.

Klein, P. G., Mahoney, J., McGahan, A., & Pitelis, C. (2012). Who is in charge? A property rights perspective on stakeholder governance. Strategic Organization, 10(3), 304–315.

Koenigsberg, O., Kohli, R., & Montoya, R. (2010). Package size decisions. Management Science, 56(3), 485–494.

Kwoka, J. E. (1998). Herfindahl concentration with an import fringe and with supply constraints. Review of Industrial Organization, 13(4), 401–407.

Kyle, M. (2007). Pharmaceutical price controls and entry strategies. Review of Economics and Statistics, 89(1), 88–99.

Leary, M. T., & Roberts, M. R. (2014). Do peer firms affect corporate financial policy? Journal of Finance, 69(1), 139–178.

Lynk, W. J. (1995). Nonprofit hospital mergers and the exercise of market power. Journal of Law and Economics, 38(2), 437–461.

Maitland, I. (2002). Priceless goods: How should life-saving drugs be priced? Business Ethics Quarterly, 12(04), 451–480.

Merrill, W., & Schneider, N. (1966). Government firms in oligopoly industries: A shortrun analysis. Quarterly Journal of Economics, 80, 400–412.

Miles, S. (2017). Stakeholder theory classification: A theoretical and empirical evaluation of definitions. Journal of Business Ethics, 142(3), 437–459.

Newhouse, J. P. (1970). Toward a theory of nonprofit institutions: An economic model of a hospital. American Economic Review, 60(1), 64–74.

Perloff, J. M., Suslow, V. Y., & Seguin, P. J. (2005). Higher prices from entry: pricing of brand name drugs. Working Paper http://are.berkeley.edu/~perloff/PDF/match05.pdf.

Personal Interview. (2014). Telephone interviews with Arjun Juneja and Sanjiv Kaul, May 5.

Prince, J., & Simon, D. (2015). Do incumbents improve service quality in response to entry? Evidence from Airlines’ on-time performance. Management Science, 61(2), 372–390.

Selvaraj, S., Hasan, H., Chokshi, M., Sengupta, A., Guha, A., Shiva, M., Srinivasan, S., Phadke, A., Gopakumar, K. M., Santhosh, M. R., & Menghaney, L. (2012). Pharmaceutical pricing policy: A critique. Economic and Political Weekly, 97(4), 20–23.

Shaked, A., & Sutton, J. (1982). Relaxing price competition through product differentiation. Review of Economic Studies, 49, 3–13.

Simon, D. (2005). Incumbent pricing responses to entry. Strategic Management Journal, 26, 1229–1248.

Smith, A. (1759). The theory of moral sentiments. A. Millar in the Strand: London.

Spinello, R. A. (1992). Ethics, pricing and the pharmaceutical industry. Journal of Business Ethics, 11(8), 617–626.

Sundaram, A. K., & Inkpen, A. C. (2004). The corporate objective revisited. Organization Science, 15(3), 350–363.

Sutton, J. (2007). Market structure: Theory and evidence. Handbook of Industrial Organization, 3, 2301–2368.

Tantalo, C., & Priem, R. L. (2016). Value creation through stakeholder synergy. Strategic Management Journal, 37(2), 314–329.

The Telegraph India. (2013). Drug price control covers too little, riddled with loopholes, November 22.

Vakili, K., & McGahan, A. M. (2016). Health care’s grand challenge: Stimulating basic science on diseases that primarily afflict the poor. Academy of Management Journal, 59(6), 1917–1939.

White, M. D. (2002). Political manipulation of a public firm’s objective function. Journal of Economic Behavior and Organization, 49, 487–499.

Wilson, R. (1992). Strategic models of entry deterrence. In R.J. Aumann & Hart, S. (Eds.), Handbook of game theory (Vol. 1, pp. 305–329). New York: Elsevier Science.

Titel: Stakeholder Orientation and Market Impact: Evidence from India
verfasst von: Arzi Adbi
Ajay Bhaskarabhatla
Chirantan Chatterjee
Publikationsdatum: 31.07.2018
Verlag: Springer Netherlands
Erschienen in: Journal of Business Ethics / Ausgabe 2/2020
Print ISSN: 0167-4544
Elektronische ISSN: 1573-0697
DOI: https://doi.org/10.1007/s10551-018-3919-x

Springer Professional

Abstract

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Weitere Artikel der Ausgabe 2/2020

How to Encourage Social Entrepreneurship Action? Using Web 2.0 Technologies in Higher Education Institutions

Sustainability Centres and Fit: How Centres Work to Integrate Sustainability Within Business Schools

How do Consumers Reconcile Positive and Negative CSR-Related Information to Form an Ethical Brand Perception? A Mixed Method Inquiry

Sustainability Orientation, Green Supplier Involvement, and Green Innovation Performance: Evidence from Diversifying Green Entrants

Responsible Practices in the Wild: An Actor-Network Perspective on Mobile Apps in Learning as Translation(s)

Implementing Socially Sustainable Practices in Challenging Institutional Contexts: Building Theory from Seven Developing Country Supplier Cases